Food Allergy News and Research

Research Suggests Eosinophilic Esophagitis Is a Late Manifestation of the Atopic March

The atopic march describes how patients who have an allergic disease are more likely to develop another or multiple allergic diseases in their lifetime. This progression commonly starts with eczema in infancy and can develop into food allergy, asthma or hay fever in childhood. Now, new research being presented at the Joint Congress provides evidence that EoE is a late but probable part of this disease progression.

Treatment for Milk Allergy Shows Positive Results in Clinical Trial

DBV Technologies today announced preliminary results from Part B, or Phase II, of a Phase I/II study evaluating the efficacy and safety of three dose regimens of Viaskin Milk (150 µg, 300 µg, 500 µg) in 198 patients for the treatment of IgE-mediated cow's milk protein allergy (CMPA). The MILES (Milk Efficacy and Safety) study was designed to determine a safe and effective dose in two age groups.

Two Peanut Allergy Treatment Trials Move Forward

Kids With Food Allergies is sharing these press releases from Aimmune Therapeutics and DBV Technologies to bring you the latest research news quickly. [PRESS RELEASE] Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy BRISBANE, Calif.– (BUSINESS WIRE) – Feb. 20, 2018 – Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced...

KFA Issues Parental Guidance Warning About New Peter Rabbit Film

The Asthma and Allergy Foundation of America (AAFA) cautions parents raising children with food allergies that some scenes in the newly-released “Peter Rabbit” film may be disturbing for young viewers with food allergies. In the film, a character with a known food allergy to blackberries is attacked with them. This leads to a severe allergic reaction known as anaphylaxis and the need to use a lifesaving injection of the drug epinephrine.

Q&A: What Does Omalizumab Mean for Oral Immunotherapy Treatment for Multiple Food Allergies?

Oral immunotherapy (OIT) is a proposed method to treat food allergy. It is currently in late-stage clinical trials (peanut specifically). It is expected to be approved by the U.S. Food and Drug Administration (FDA) soon. There have been many clinical trials for specific food OIT alone and with medicines, such as omalizumab, as reported in this study.

Omalizumab Makes Oral Immunotherapy Treatments More Effective

Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, new clinical trial findings show. After 36 weeks, more than 80 percent of children who received omalizumab and OIT could safely consume two-gram portions of at least two foods to which they were allergic, compared with only a third of children who received placebo and OIT.

First Epinephrine Auto-Injector for Infants and Small Children Will Be Available in 2018

kaléo today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for AUVI-Q® (epinephrine injection, USP) 0.1 mg, the first and only epinephrine auto-injector (EAI) specifically designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and small children weighing 16.5 to 33 pounds (7.5 to 15 kilograms) who are at risk for or have a history of serious allergic reactions.

Kids With Food Allergies
A Division of the Asthma and Allergy Foundation of America
8201 Corporate Drive Suite 1000 Landover, MD 20785
Phone: 1-800-7-ASTHMA (1.800.727.8462)
-->
×
×
×
×